Advertisement
week in cancer news
  • December 3: The Week in Cancer News

    Some cancer centers scrutinized for lack of pricing transparency, and an imaging drug helps surgeons better identify ovarian cancer with fluorescent lighting.

    by Marci A. Landsmann

  • November 19: The Week in Cancer News

    HPV vaccine rates are higher when teens decide, and colorectal cancer is on the rise in people under 50.

    by Kevin McLaughlin

  • November 12: The Week in Cancer News

    The U.S. Is behind the U.K. in preventing cervical cancer through HPV vaccination, and lack of health insurance impacts cancer screening in the unemployed.

    by Eric Fitzsimmons

  • November 5: The Week in Cancer News

    U.S. map spotlights industrial hot spots for cancer-causing air pollution, and surgery delays after initial treatment impact survival for some patients with locally advanced rectal cancer.

    by Marci A. Landsmann

  • October 29: The Week in Cancer News

    Patient expenses for cancer care exceed $21 billion in 2019, and the FDA introduces stringent requirements for breast implants.

    by Kevin McLaughlin

  • October 22: The Week in Cancer News

    Researchers suggest Black women should be screened for breast cancer at age 40, and a couple reflect on how a cancer diagnosis affected their adoption journey.

    by Bradley Jones

  • October 15: The Week in Cancer News

    FDA authorizes electronic cigarette for the first time, and a new survey explores marijuana use in breast cancer patients

    by Eric Fitzsimmons

  • October 8: The Week in Cancer News

    A study shows the cost of drugs that manage cancer-related symptoms adds up, and experts explore research at the AACR conference on cancer disparities.

    by Marci A. Landsmann

  • October 1: The Week in Cancer News

    MRI can be a cost-effective way to screen for breast cancer, and a new study investigates the impact of higher alcohol taxes on cancer incidence

    by Kevin McLaughlin

  • September 24: The Week in Cancer News

    Long-term COVID-19 effects were associated with greater mortality risk in cancer patients, and a new study compares HER2-targeted therapies in metastatic breast cancer.

    by Eric Fitzsimmons